Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

enGene Therapeutics Inc.

ENGN ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.63

▼ -2.40%

Market Cap $109.24M · Vol 384.73K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$109.24M

Micro Cap

Div Yield

N/A

EPS Growth

+20.98%

YoY

RSI (14)

30.56

Momentum

Beta

-0.28

vs Market

52W High

$12.24

86.36% below

52W Low

$1.41

18.86% above

Volume

384.73K

Avg 203.47K

P/B

2.24

Price-to-book

ROE

-53.28%

Return on equity

Free Float

92.69%

Public shares

Shariah Compliance8 STANDARDS

✗ enGene Therapeutics Inc. (ENGN) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ENGN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.49%

-16.84%

-15.54%

-80.85%

YTD

-81.95%

-80.82%

-83.93%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-117,302,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-53.28%
ROA · ROIC	-44.05% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.24
P/FCF	N/A
EPS Growth	+20.98%
Outstanding Shares	67.02M

Technical Indicators

50-Day SMA	$1.82
200-Day SMA	$4.61
RSI (14)	30.56
Beta	-0.28
52-Week High	$12.24
52-Week Low	$1.41

Volume Today	384.73K
Avg Daily Volume (30D)	203.47K
Relative Volume	1.89x
Volatility (10D)	71.51
Volatility (30D)	53.81
Free Float	92.69%

Analyst Consensus

BUY

Current Price $1.63

Mean Target $7.65

52W Low$1.41 52W High$12.24

Current

Target

$1.41 $12.24

Current Analyst target

+369.33% upside potential · 10 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG01J1GCYX6

ISINCA29286X1015

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateDec 21, 2026

TypeStocks

Instrument TypeUNT Unit

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -0.25% ARGX.BR argenx SE +0.82% ARGX argenx SE +2.34% 2269.HK WuXi Biologics (Cayman) Inc. -1.30% GMAB Genmab A/S +1.28%

Company Profile

enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).